Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2012 by Centre Muraz.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Institute of Tropical Medicine, Belgium
Information provided by (Responsible Party):
Centre Muraz
ClinicalTrials.gov Identifier:
NCT01697787
First received: September 29, 2012
Last updated: April 19, 2013
Last verified: October 2012

September 29, 2012
April 19, 2013
October 2012
December 2012   (final data collection date for primary outcome measure)
Rate of treatment failures [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
The rate of the two ACTs treatment failures at day 28: all treatment failures, both parasitological and clinical (positive blood slide at day 28)
Same as current
Complete list of historical versions of study NCT01697787 on ClinicalTrials.gov Archive Site
RDT performance Vs microscopy [ Time Frame: 28 days ] [ Designated as safety issue: No ]
The proportion of discrepancies between the RDT and the microscopy results
Same as current
  • Fever clearance time (FCT) Fever Clearance Time [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Fever clearance time will be defined as the time (in days) from the time of the drug administration to the first two consecutive measurements on 2 different days of axillary temperature below 37.5°C
  • Gametocytes carriage [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Gametocytes carriage including the estimation of the prevalence and density
Same as current
 
Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso
Efficacy of Amodiaquine-Artesunate (ASAQ) and Artemether-Lumefantrine (AL) for the Treatment of Uncomplicated Falciparum Malaria in Nanoro, Burkina Faso

This is a two-arm study aiming at recruiting 150 patients to assess the efficacy of Amodiaquine-Artesunate (ASAQ) and Artemether-Lumefantrine (AL) in patients with a microscopy positive diagnosis of malaria in Nanoro, Burkina Faso and assess the performance of the Rapid Diagnosis Tests (RDTs) compared to the microscopy.

Study background and purpose

  • Resistance to usual drugs was widespread and has required a change of the malaria treatment by several countries
  • Several countries have changed their first-line treatments to ACTs; mainly AL and ASAQ. & have adopted the use of RDTs prior to treatment
  • Indeed, this contributes to decrease the number of unnecessary treatments and thus improve the management of malaria cases.
  • In February 2005, Burkina Faso changed its national drug policy from Chloroquine to Amodiaquine-Artesunate (ASAQ) and Artemether-Lumefantrine (AL)
  • the country has also implemented the strategy of using the Rapid Diagnosis Tests (RDTs) for the diagnosis of malaria prior to treatment
  • Though endemic countries are being encouraged to implement RDTs, choosing a particular RDT is not easy as several brands are available on the market.
  • In addition, little information on the performance of RDTs in Africa is available and recently quality problems have been reported with some RDTs.
  • In this context, it is important to locally assess the performance of RDTs compared with the microscopy, which is the gold standard for the malaria diagnosis and to assess the efficacy of the new drugs used for malaria treatment

This is a phase IV two-arm randomized open-label study aiming at recruiting 150 patients to assess the efficacy of ASAQ and AL in patients with a microscopy positive diagnosis of malaria in Nanoro, Burkina Faso and assess the performance of the RDT compared to the microscopy

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Malaria
  • Drug: Amodiaquine-Artesunate
    If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
    Other Name: ASAQ Winthrop, Coarsucam
  • Drug: Artemether-lumefantrine
    If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
    Other Name: Coartem, Riamet
  • Amodiaquine-Artesunate
    ASAQ is produced by Sanofi-Aventis as CoarsucamTM and as artesunate-amodiaquine Winthrop®
    Intervention: Drug: Amodiaquine-Artesunate
  • Artemether-Lumefantrine
    AL (tablets containing 20 mg of artemether and 120 mg of lumefantrine) is produced by Novartis
    Intervention: Drug: Artemether-lumefantrine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
150
June 2013
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age above 6 months,
  • eight above 5 kg;
  • Positive blood slide (parasitaemia ≥ 2,000/μL to 200,000/μL) with Plasmodium falciparum monospecific infection ;
  • Fever (axillary temperature above 37.5 °C) or history of fever in the preceding 24 hours;
  • Haemoglobin value above or equal 5.0 g/dL
  • Signed informed consent;
  • Willingness and ability to comply with the study protocol for the duration of the trial.

Exclusion Criteria:

  • Participation in any other investigational drug study (antimalarial or others) during the previous 30 days
  • Known hypersensitivity to the study drugs
  • Severe malaria
  • Danger signs: not able to drink or breast-feed, vomiting (> twice in 24hours), recent history of convulsions (more than 1 in 24h), unconscious state, unable to sit or stand;
  • Known intercurrent illness or any condition (cardiac, renal, hepatic diseases) which would place the subject at undue risk or interfere with the results of the study.
  • Severe malnutrition (defined as weight for height less than 70% of the median NCHS/WHO reference)
  • Known pregnancy
Both
6 Months to 90 Years
No
Contact information is only displayed when the study is recruiting subjects
Burkina Faso
 
NCT01697787
CM/CRUN0012
No
Centre Muraz
Centre Muraz
Institute of Tropical Medicine, Belgium
Study Director: Halidou Tinto, PharmD, PhD IRSS/Centre Muraz
Centre Muraz
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP